Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study (CNS Drugs, (2022), 36, 9, (977-993), 10.1007/s40263-022-00950-0)
Jai Perumal*, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer, Steven L. Galetta, Robin L. Avila, Danette Rutledge, Robert J. Fox
Dive into the research topics of 'Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study (CNS Drugs, (2022), 36, 9, (977-993), 10.1007/s40263-022-00950-0)'. Together they form a unique fingerprint.